These are the details for the profile Development and commercialization of biomarker-based assays.
If you would like more information about the profile please click Request More
Information. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A Spanish biotechnology company specialized and focused on the development and commercialization of biomarker-based assays, is looking for partners to develop new protein and antibodies arrays and ELISA diagnostic kits that could be useful in diagnostic or prognostic of several pathologies, mainly cancer. The company would like to develop innovative research projects, through the establishment of strategic alliances by outsourcing, services or manufacturing agreements.
The Spanish biotechnology company is focused on the development and commercialization of biomarker-based assays for cancer diagnosis and clinical management, and also offers its own manufactured innovative recombinant proteins and antibodies, different custom-tailored integral services in protein design and expression. The service offered is performed under individual customer contracts (CRO) to meet biotechnology industry needs.
It is one of the few companies in the Spanish sector able to offer three different expression systems for proteins production, allowing the customers to obtain active proteins and optimized proteins according to each project. The company has wide experience in antibody technology (such as phage display), ScFv / Fab (antibodies) production, construction of Murine and Human phage antibody library, antibody humanization, among others.
The company has distribution agreements with worldwide distributors of recombinant proteins and antibodies for research.
The company has a strong expertise and has developed R&D projects for biotech, pharmaceutical companies, research centres, universities and hospital as CRO since 2006.
The company would like to develop innovative research projects, including the establishment of strategic alliances with other pharmaceutical companies, hospitals and academic institutions, to develop new protein and antibodies arrays and ELISA diagnostic kits that could be useful in diagnostic or prognostic of several pathologies, mainly the cancer.
The way to stablish these alliances is thought to be trough any of these ways:
- Outsourcing agreement: as a provider partner of recombinant proteins or antibodies, or diagnostic kits related to protein expression, specially tested for genomic and proteomic applications, including tissue immunohistochemistry.
- Services agreement: to develop any specific assay or kit for the interested partner related to:
o Protein expression and purification
o Polyclonal antibody production
o Monoclonal antibody production
o Recombinant antibody technology
- Manufacturing agreement: developer and supplier partner of biomarker-based assays. Offering tailored integral services (CRO), performed under individual customer contracts, in areas like: (i) recombinant protein expression of different organisms: Homo sapiens, Mouse, Xenopus and others, in prokaryotic or eukaryotic systems: Escherichia coli, baculovirus and mammalian cells; (ii) recombinant protein purification using several tags: Hisx6, MBP, GST or others; (iii) specific, polyclonal and monoclonal antibody generation.
The company strength is a strong knowledge of protein and antibody design, development and production. In this sense, its additional goal is to offer different products and custom-tailored services, mainly related to proteins and antibodies production and/or protein expression, to meet the needs of the academic and biotechnology industry. The company offers own-manufactured innovative proteins and antibodies, some of them exclusively provided by them, and specialized services in protein design and production based on three different expression systems: E. coli (bacterial), Baculovirus in insect cells and mammalian cells.
The Spanish biotechnology company is interested in establishing strategic alliances with pharmaceutical companies, hospitals and academic institutions that may need new developments of protein and antibodies arrays and ELISA diagnostic kits, in diagnostic or prognostic of several pathologies, mainly the cancer.
The alliances are expected to be through outsourcing, services or manufacturing agreements.